Clinical Trials
12 trialsNCT02453282 2026-05-12
MYSTIC
AstraZeneca
Phase 3 Active not recruiting
NCT02542293 2026-05-01
NEPTUNE
AstraZeneca
Phase 3 Active not recruiting
NCT03003962 2026-03-11
Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)
AstraZeneca
Phase 3 Active not recruiting
NCT06430437 2026-01-21
A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Recruiting
NCT03519971 2025-10-28
Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer
AstraZeneca
Phase 3 Active not recruiting
NCT03737643 2025-01-29
DUO-O
AstraZeneca
Phase 3 Active not recruiting
NCT06008106 2024-06-28
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
Shanghai Kechow Pharma, Inc.
Phase 3 Recruiting
NCT02855944 2023-06-09
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
pharmaand GmbH
Phase 3 Completed
NCT00576225 2020-10-19
CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL
CTI BioPharma
Phase 3 Withdrawn
NCT00254891 2015-03-30
Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer
Pfizer
Phase 3 Terminated
NCT00111007 2014-10-31
A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma
Bayer
Phase 3 Completed
NCT00087802 2009-04-16
Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC)
Sanofi
Phase 3 Completed